CWM Advisors LLC lowered its position in Illumina, Inc. (NASDAQ:ILMN) by 18.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,143 shares of the life sciences company’s stock after selling 491 shares during the quarter. Illumina accounts for about 0.2% of CWM Advisors LLC’s holdings, making the stock its 23rd largest position. CWM Advisors LLC’s holdings in Illumina were worth $643,000 at the end of the most recent reporting period.
Several other hedge funds have also recently made changes to their positions in ILMN. Moody National Bank Trust Division bought a new position in shares of Illumina during the 4th quarter worth approximately $31,000. Arcadia Investment Management Corp MI bought a new position in shares of Illumina during the 4th quarter worth approximately $39,000. Exane Derivatives lifted its position in shares of Illumina by 12,900.0% during the 4th quarter. Exane Derivatives now owns 130 shares of the life sciences company’s stock worth $39,000 after buying an additional 129 shares during the period. Alpha Windward LLC bought a new position in shares of Illumina during the 4th quarter worth approximately $77,000. Finally, CENTRAL TRUST Co lifted its position in shares of Illumina by 1,325.0% during the 4th quarter. CENTRAL TRUST Co now owns 285 shares of the life sciences company’s stock worth $85,000 after buying an additional 265 shares during the period. Institutional investors own 88.94% of the company’s stock.
Shares of Illumina stock opened at $281.87 on Wednesday. The stock has a market capitalization of $41.31 billion, a PE ratio of 49.28, a PEG ratio of 2.00 and a beta of 1.20. Illumina, Inc. has a one year low of $207.51 and a one year high of $372.61. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.24 and a current ratio of 2.46.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, January 29th. The life sciences company reported $1.32 EPS for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.04). The firm had revenue of $867.00 million during the quarter, compared to the consensus estimate of $865.33 million. Illumina had a net margin of 24.79% and a return on equity of 25.44%. The business’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter last year, the firm earned $1.44 earnings per share. Analysts predict that Illumina, Inc. will post 6.53 earnings per share for the current fiscal year.
ILMN has been the subject of several analyst reports. UBS Group upgraded Illumina from a “neutral” rating to a “buy” rating and raised their target price for the stock from $340.00 to $370.00 in a research report on Thursday, January 3rd. Morgan Stanley cut their target price on Illumina from $320.00 to $288.00 and set an “equal weight” rating for the company in a research report on Monday, January 7th. BidaskClub downgraded Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, October 16th. ValuEngine downgraded Illumina from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 11th. Finally, Deutsche Bank raised their target price on Illumina to $350.00 and gave the stock a “buy” rating in a research report on Friday, October 12th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and twelve have issued a buy rating to the company’s stock. Illumina currently has an average rating of “Buy” and an average price target of $346.40.
In other news, SVP Charles Dadswell sold 566 shares of the business’s stock in a transaction dated Monday, December 3rd. The stock was sold at an average price of $343.57, for a total value of $194,460.62. Following the sale, the senior vice president now directly owns 5,606 shares in the company, valued at $1,926,053.42. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Francis A. Desouza sold 3,000 shares of Illumina stock in a transaction dated Friday, February 1st. The shares were sold at an average price of $282.95, for a total value of $848,850.00. Following the completion of the sale, the insider now directly owns 66,904 shares in the company, valued at approximately $18,930,486.80. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 49,247 shares of company stock worth $15,204,166. Corporate insiders own 0.54% of the company’s stock.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Further Reading: Liquidity
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.